title: [Radical prostatectomy in stage pT3C stage prostatic adenocarcinoma].
abstract: OBJECTIVE
  To assess the efficacy of surgery in pT3c patients; to discern whether this is an independent influential factor for survival and clinical factor for diagnostic prediction.
  
  
  METHODS
  Forty-five pT3c (TNM 1982) patients from a cohort of 220 subjects with T1-T2 prostate cancer who underwent radical prostatectomy. Mean and median follow-up: 42 and 36 months, respectively.
  
  
  RESULTS
  pT3 stage accounts for 20% (45/220) patients. They display a significantly higher mean PSA (25 +/- 2 ng/ml) (0.001), worse Gleason (0.0002) and clinical stage (0.0003), greater margins involvement (0.0007), and biochemical (0.02), local (0.05) and metastatic (0.001) progression. Independent influential factors are: PSA > 20 ng/ml; T2bc and Gleason 7-10. From these values patients can be divided into 3 risk groups: a) Group I (0-1 unfavourable variables): risk of seminal vesicle involvement 7%; Group II (2 unfavourable variables): risk 47%; Group III (3 unfavourable variables): risk 61%. Progression-free survival: significantly lower than patients with pT2 (58 +/- 8% vs 66 +/- 6% at 5 years) (0.002), but similar to those with pT3ab (0.91). Seminal vesicle involvement is not an independent influential factor (Cox's multivariate study). Influential factors are PSA, Gleason and clinical stage.
  
  
  CONCLUSIONS
  pT3c tumours are not an independently influential group in progression-free survival. Progression-free survival is lower than pT2 but similar to pT3ab. Their poor prognosis is dependent on association to negatively influential clinico-pathological factors.
authors.affiliation: Departamento de Urología, Clínica Universitaria de Navarra, Universidad de Navarra, Pamplona.
authors.forename: J J
authors.initials: JJ
authors.lastname: Zudaire Bergera
authors.forename: J
authors.initials: J
authors.lastname: López Ferrándiz
authors.forename: D
authors.initials: D
authors.lastname: Sánchez Zalabardo
authors.forename: J
authors.initials: J
authors.lastname: Arocena García-Tapia
authors.forename: G
authors.initials: G
authors.lastname: Sanz Pérez
authors.forename: F
authors.initials: F
authors.lastname: Díez Caballero
authors.forename: D
authors.initials: D
authors.lastname: Rosell Costa
authors.forename: J E
authors.initials: JE
authors.lastname: Robles García
authors.forename: J M
authors.initials: JM
authors.lastname: Berián Polo
mesh_terms: D000230:Adenocarcinoma / Q000401:mortality / Q000473:pathology / Q000601:surgery*; D000368:Aged; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000401:mortality / Q000473:pathology / Q000601:surgery*; D015996:Survival Rate